Robeco Institutional Asset Management B.V. Has $2.55 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Robeco Institutional Asset Management B.V. lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 22.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,761 shares of the medical research company's stock after selling 2,239 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Bio-Rad Laboratories were worth $2,550,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. UMB Bank n.a. grew its position in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $32,000. Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories during the third quarter worth approximately $55,000. Livforsakringsbolaget Skandia Omsesidigt grew its position in Bio-Rad Laboratories by 281.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company's stock worth $91,000 after buying an additional 200 shares in the last quarter. Finally, Quarry LP increased its stake in Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company's stock worth $99,000 after acquiring an additional 82 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BIO shares. Royal Bank of Canada reiterated an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $394.20.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock traded down $3.72 during midday trading on Friday, reaching $341.69. The company's stock had a trading volume of 231,287 shares, compared to its average volume of 156,351. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a market cap of $9.57 billion, a PE ratio of -12.50 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The business has a 50-day moving average price of $341.16 and a 200-day moving average price of $336.46.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.